Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the month of September 2021. The company is a foreign private issuer with its principal executive office located in Jena, Germany.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
Effective September 13, 2021, Lina Ma resigned as a Director of the Board of Directors. The company explicitly stated that Ms. Ma's resignation was not due to any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the board member's resignation.
Key Facts for Investors to Verify
- Confirmation of the effective date of Lina Ma's resignation (September 13, 2021).
- Whether the Board has appointed a replacement director to fill the vacancy.
- Any potential impact of this personnel change on ongoing clinical trials or strategic direction.